Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
Author:
Funder
Pfizer
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/article/10.1007/s10549-018-4827-6/fulltext.html
Reference29 articles.
1. Boér K (2016) Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer. Onco Targets Ther 9:6119–6125
2. Maurer C, Martel S, Zardavas D, Ignatiadis M (2017) New agents for endocrine resistance in breast cancer. The Breast 34:1–11
3. Almstedt K, Schmidt M (2015) Targeted therapies overcoming endocrine resistance in hormone receptor-positive breast cancer. Breast Care (Basel) 10(3):168–172
4. Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28(1):16–33
5. Augereau P, Patsouris A, Bourbouloux E et al (2017) Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. Ther Adv Med Oncol 9(5):335–346
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer;Cancer Biology & Therapy;2023-10-13
2. Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study;Cancer Medicine;2022-04-25
3. Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study;Annals of Translational Medicine;2021-04
4. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study;Therapeutic Advances in Medical Oncology;2021-01
5. Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report;Tumori Journal;2020-12-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3